Search
Gaucher Association Logo

Promoting awareness, pioneering research and providing support and information for those affected by Gaucher disease.

NEED SUPPORT TODAY?

Telephone: 01453 549231
Email: ga@gaucher.org.uk

In the News

  • Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the European Working Group on Gaucher disease

    7 January 2010

    Blood Cells, Molecules, and Diseases - 18th December 2009: Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the European Working Group on Gaucher disease, click here to see the full paper.

  • Shire Submits European Marketing Authorization

    25 November 2009

    Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease Committee for Medicinal Products for Human Use (CHMP) Grants Accelerated Assessment

    Dublin, Ireland ' 24 November …

    read more »

  • Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

    23 October 2009

    Based on the findings of the meeting of the EWGGD on Thursday 10th September in Bad Honnef, Germany, this paper includes a position statement based on the findings of the meeting, the key recommendations for the identification and monitoring of …

    read more »

  • Cerezyme Emergency Treatment Program

    30 September 2009

    Dear Friends,

    I am writing to inform you of some very important developments in the management of the shortage of Cerezyme, which is so severely affecting Gaucher patients globally.

    An Emergency meeting of the European Working Group on Gaucher …



    read more »

  • Cerezyme Supply Update

    20 August 2009

    Dear Friends, I am writing to you, at what is a very difficult time for the global Gaucher community, to provide an update on the supply of Cerezyme and how the matter is being dealt with in the UK.

    As you will no doubt be aware, on the …

    read more »

  • Shire files treatment protocol

    9 July 2009

    Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease

    Lexington, Massachusetts, US – July 6th, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that, at the …

    read more »

  • Protalix Approached by the FDA

    6 July 2009

    Protalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD

    CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), …

    read more »

  • Cerezyme Supply

    18 June 2009

    Genzyme Temporarily Interrupts Production at Allston Plant

    • Genzyme announce temporary closure of Boston manufacturing plant : Read Genzyme press release
    • Currently waiting for news of Cerezyme availability for next week
    • UK …

    read more »

  • Small Grant for Type 2 Research

    1 May 2009

    The Gauchers Association has awarded a small grant to The Royal Free Hospital, London to purchase a batch of viral vectors as part of their research in gene therapy in Type II Gaucher disease.

  • Protalix Switch over Trial

    23 March 2009

    Protalix BioTherapeutics Announces First Patient Enrolled in Open-Label, Switchover Trial of prGCD for the Treatment of Gaucher Disease

    Protalix BioTherapeutics, Inc. (Amex: PLX), has announced enrollment of the first patient in a worldwide, …

    read more »